96 Tests PN: B113368
45x Ab-conjugated beads (S5P10 - human sCD30L Ab-bead). PN: B113368A. One vial containing 100 µL of anti-human sCD30L conjugated to AimPlex Bead S5P10.
25x Biotin-detection Ab (human sCD30L Biotin-dAb). PN: B113368B. One vial containing 100 µL of biotinylated anti-human sCD30L
Lyophilized Standard Mix-Human Group 5 Panel A, 8-Plex. PN: HG50008. One vial containing lyophilized recombinant human sE-Cadherin, sLIGHT, sTRAIL-R3, s4-1BB, sCD30L, sVEGFR2, BlyS, and sPECAM-1. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.
Application: Optimal antibody pair and antigen standard for assaying human TNFSF8/sCD153/sCD30L . Can be multiplexed with other analytes in Human Group 5. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.
Storage: 2-8 C in the dark.
Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.
For Research Use Only. Not for use in diagnostic procedures.
Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate
Sensitivity (LOD): < 40 pg/mL
LLOQ: < 70 pg/mL
ULOQ: > 50,000 pg/mL
Standard dose recovery: 70-130%
Intra-assay CV: < 10%
Inter-assay CV: < 20%
Cross-reactivity of analytes in Human Group 5: Negligible
Sample volume: 15 µL/test
Tumor Necrosis Factor Receptor SuperFamily, Member 8 (TNFSF8) also known as CD30 ligand (CD30L) and CD153, is a type II membrane protein belonging to the TNF superfamily. CD30L is expressed on the cell surface of activated T cells, B cells, and monocytes. The protein is also constitutively expressed on granulocytes and medullary thymic epithelial cells. The specific receptor for CD30L is CD30/TNFRSF8, a type I transmembrane glycoprotein belonging to the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkin's and Reed-Sternberg cells using the monoclonal antibody Ki-1. CD30 is also expressed on different non-Hodgkin's lymphomas, virus-infected T and B cells, and on normal T and B cells after activation. Among T cells, CD30 is preferentially expressed on a subset of T cells producing Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and IL-4 receptor. CD30 ligation by CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation and cell death by apoptosis. It is expressed in embryonal carcinoma but not in seminoma and is thus a useful marker in distinguishing between these germ cell tumors. CD30 can act as a co-stimulatory molecule in thymic negative selection and may also play a critical role in the pathophysiology of Hodgkin's disease, spastic diplegia and other CD30+ lymphomas.
Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL (Nov 2005). "[Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors]". Zhonghua Bing Li Xue Za Zhi Chinese Journal of Pathology (in Chinese) 34 (11): 711–5. PMID 16536313.
Gorczyca W, Tsang P, Liu Z, Wu CD, Dong HY, Goldstein M, Cohen P, Gangi M, Weisberger J (Feb 2003). "CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis". International Journal of Oncology 22 (2): 319–24. doi:10.3892/ijo.22.2.319. PMID 12527929.
Deng C, Pan B, O'Connor OA (Jan 2013). "Brentuximab vedotin". Clinical Cancer Research 19 (1): 22–7. doi:10.1158/1078-0432.CCR-12-0290. PMID 23155186.